- 3Q Net Sales: M3 Inc. reported net sales of 80.70 billion yen, showing a 27% increase year-over-year, surpassing the estimate of 77.28 billion yen.
- Operating Income: The company’s operating income rose by 3.5% year-over-year to 21.12 billion yen, beating the projected 20.38 billion yen.
- Net Income: M3 Inc.’s net income increased by 15% year-over-year, reaching 15.25 billion yen, exceeding the expected 13.96 billion yen.
- Year Forecast: M3 Inc. maintains its forecast for operating income between 67.00 billion yen and 70.00 billion yen, higher than the market estimate of 64.81 billion yen.
- Net Income Forecast: The company continues to predict net income between 44.00 billion yen and 46.00 billion yen, above the estimated 42.44 billion yen.
- Net Sales Forecast: M3 Inc. anticipates net sales between 268.00 billion yen and 273.00 billion yen in spite of a market estimate of 273.73 billion yen.
- Analyst Recommendations: The company’s stock has 6 buy ratings, 8 hold ratings, and 1 sell rating.
M3 Inc on Smartkarma
On Smartkarma, an independent investment research network, Shifara Samsudeen, ACMA, CGMA, has published a bearish analysis on M3 Inc. In the report titled “M3: Earnings Trend Downward, ELAN Acquisition to Further Dilute Margins,” it is highlighted that M3’s share price has dropped over 18% following its 2Q earnings release. Both revenue and operating profit fell below consensus, with a surprising drop in operating profit margin for the quarter. The Medical Platform segment’s earnings have been declining due to spending cuts by pharmaceutical companies, while other segments have not been able to offset this decline. The recent majority stake acquisition of ELAN by M3 is expected to further dilute the company’s margins, with previous M&A deals failing to significantly boost consolidated earnings.
A look at M3 Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 2 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, M3 Inc shows a mixed long-term outlook. While the company’s Value, Dividend, and Growth scores are moderate, indicating room for improvement in these areas, it demonstrates strong Resilience with a score of 4. This suggests that M3 Inc is positioned well to weather economic uncertainties and market volatility. Additionally, the Momentum score of 3 highlights a positive trend in the company’s performance. Overall, M3 Inc‘s resilience and momentum could potentially drive its long-term success in the medical information services sector.
As a provider of medical information services for doctors through the Internet, M3 Inc also supports marketing efforts for pharmaceutical companies and medical equipment manufacturers. With a focus on enhancing the healthcare industry’s efficiency and effectiveness, M3 Inc plays a vital role in facilitating communication and access to critical information within the medical community. By leveraging its technological capabilities and industry partnerships, M3 Inc is poised to capitalize on the growing demand for digital healthcare solutions, boding well for its future growth and sustainability.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
